Review Article
Volume 18 Issue 5 - 2022
MicroRNA: A Novel Approach for the Treatment and Vaccination of COVID-19
Bati Leta* and Urge Gerema
Department of Biomedical Sciences, Division of Medical Biochemistry, College of Medical Sciences, Institute of Health Sciences, Jimma University, Ethiopia
*Corresponding Author: Bati Leta, Department of Biomedical Sciences, Division of Medical Biochemistry, College of Medical Sciences, Institute of Health Sciences, Jimma University, Ethiopia.
Received: October 12, 2021; Published: April 22, 2022




Abstract

MicroRNA (miRNA) is a small non-coding ribonucleic acid (RNA) molecule that executes a vital role in the post-transcriptional gene regulation of messenger RNA. Many messenger RNAs (mRNAs) are regulated by specific miRNAs to mediate cellular proliferation, differentiation, and signaling. SARS-CoV-2 is a novel severe pathogenic coronavirus that causes the coronavirus disease 2019 (COVID-19). Cellular miRNA is a valuable determination point to get the underlying pathological process of COVID-19. Given the possibility of a pandemic, researchers and clinicians have been rushing to comprehend this novel virus and the pathogenesis of this disease in order to develop feasible treatment regimens and efficient therapeutic drugs and vaccinations. Many approaches are being used to manage the irruption of this fatal infectious agent disease. miRNA, being the emerging magnificent signature of response to host-viral interactions, has recently been used to develop therapeutics and vaccine against viral diseases. The aim of this review was to describe the role of miRNAs in the pathogenesis of COVID-19 while also establishing the scholarly foundation for future COVID-19 therapeutic drugs and vaccines development.

Keywords: COVID-19; Microrna; SARS- Cov-2

References

  1. Maxmen A. “Bats exposed as main coronavirus carrier”. Nature 7658 (2017): 340.
  2. Stadler K., et al. “SARS - beginning to understand a new virus”. Nature Reviews Microbiology 3 (2003): 209-218.
  3. Masters PS. “The Molecular Biology of Coronaviruses”. Advances in Virus Research 65 (2006): 193-292.
  4. Su S., et al. “Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses”. Trends in Microbiology6 (2016): 490-502.
  5. Zhu N., et al. “A Novel Coronavirus from Patients with Pneumonia in China, 2019”. The New England Journal of Medicine8 (2020): 727-733.
  6. Hasan M., et al. “A Computational Approach for Predicting Role of Human MicroRNAs in MERS-CoV Genome”. Advances in Bioinformatics (2014): 1-8.
  7. Mousavizadeh L nand Ghasemi S. “Genotype and phenotype of COVID-19: Their roles in pathogenesis”. Journal of Microbiology, Immunology and Infection (2020): 1-5.
  8. Li X., et al. “Molecular immune pathogenesis and diagnosis of COVID-19”. Journal of Pharmaceutical Analysis2 (2020): 102-108.
  9. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19”. The New England Journal of Medicine8 (2021): 693-704.
  10. Tang B., et al. “An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)”. Infectious Disease Modelling 5 (2020): 248-255.
  11. Lu H. “Drug treatment options for the 2019-new coronavirus (2019-nCoV)”. BioScience Trends (2020): 10-12.
  12. Id AM., et al. “MicroRNA-8073: Tumor suppressor and potential therapeutic treatment”. PLoS One12 (2018).
  13. Bidarra D., et al. “Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction”. Frontiers in Oncology900 (2019).
  14. Chakraborty M., et al. “A Statistical Analysis of MicroRNA: Classification, Identification and Conservation Based on Structure and Function (2015).
  15. Bai X., et al. “The MicroRNA Family Both in Normal Development and in Different Diseases : The miR-17-92 Cluster”. BioMed Research International (2019): 11.
  16. Gebert LFR and Macrae IJ. “Regulation of microRNA function in animals”. Molecular and Cellular Biology 21 (2019).
  17. Yu H., et al. “Circulating MicroRNA Biomarkers for Lung Cancer Detection in East Asian Populations”. Cancers 415 (2019).
  18. Poduri R., et al. “Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19”. Cell Signal 74 (2020): 1-64.
  19. Tang X., et al. “On the origin and continuing evolution of SARS-CoV-2 Xiaolu”. Microbiology (2020): 1-24.
  20. Yuki K., et al. “COVID-19 pathophysiology: A review”. Clinical Immunology 215 (2020): 1-8.
  21. Tikellis C and Thomas MC. “Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease”. International Journal of Peptide Research and Therapeutics (2012): 1-9.
  22. Gheblawi M., et al. “Angiotensin Converting Enzyme 2 : SARS-CoV-2 Receptor and Regulator of the Renin- Angiotensin System”. Circulation Research (2020): 1-35.
  23. Oda S., et al. “miRNA in Rat Liver Sinusoidal Endothelial Cells and Hepatocytes and Application to Circulating Biomarkers that Discern Pathogenesis of Liver Injuries”. The American Journal of Pathology 1 (2018): 1-13.
  24. Abdel-Ghany S and Sabit H. “microRNA-Based Vaccination and Treatment for COVID-19”. Current Trends in Vaccines and Vaccinology (2020): 1-2.
  25. Elnabi SEH. “New strategies for treatment of COVID-19 and evolution of SARS-CoV-2 according to biodiversity and evolution theory”. Egyptian Journal of Basic and Applied Sciences1 (2020): 226-232.
  26. Cui J., et al. “Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirus”. Journal of Virology304 (2013): 1-5.
  27. Chauhan N., et al. “COVID-19: fighting the invisible enemy with microRNA”. Expert Review of Anti-infective Therapy9 (2020): 1-24.
  28. Liu W., et al. “Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV”. Chemical Biology (2019): 1-24.
  29. Du L., et al. “The spike protein of SARS-CoV - a target for vaccine and therapeutic development”. Microbiology 7 (2009): 226-236.
  30. Matsuyama S., et al. “Enhanced isolation of SARS-CoV-2 by TMPRSS2- expressing cells”. Proceedings of the National Academy of Sciences of the United States of America17 (2020): 7000-7003.
  31. Ling H. “Non-coding RNAs: Therapeutic Strategies and Delivery Systems”. Advances in Experimental Medicine and Biology (2016): 229-237.
  32. Rupaimoole R and Slack FJ. “MicroRNA therapeutics: towards a new era for the management of cancer and other diseases”. Drug Discovery (2017): 1-19.
  33. Sardar R., et al. “Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis”. BioRxIv (2020): 1-22.
  34. Zhdanov VP. “Intracellular miRNA or siRNA delivery and function”. Bio Systems (2018): 1-34.
  35. Ivashchenko A., et al. “The miRNA COMPLEXES AGAINST CORONAVIRUSES COVID-19, SARS-CoV, and MERS-CoV”. Research Square (2016): 1-16.
  36. Demirci MDS Adan and A. “Computational analysis of microRNA- mediated interactions in SARS-CoV-2 infection”. Peer Journal 8 (2020): 1-17.
  37. Greenwood B., et al. “The contribution of vaccination to global health : past , present and future Author for correspondence”. Philosophical Transactions of the Royal Society B 369 (2014): 20130433.
  38. Andre FE., et al. “Vaccination greatly reduces disease, disability, death and inequity worldwide”. Bulletin of the World Health Organization2 (2008): 140-146.
  39. Huang Y., et al. “Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19”. Acta Pharmacologica Sinica9 (2020): 1141-1149.
  40. Xia S., et al. “Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein”. Cellular and Molecular Immunology7 (2020): 765-767.
  41. Liu C., et al. “Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases”. ACS Central Science3 (2020): 315-331.
  42. Wang N., et al. “Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses”. Frontiers in Microbiology298 (2020): 1-19.
  43. Sabit Hussein A-GS. “microRNA-Based Vaccination and Treatment for COVID-19”. Current Trends in Vaccines and Vaccinology1 (2020): 109.
  44. Padron-Regalado E. “Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains”. Infectious Diseases and Therapy2 (2020): 255-274.
  45. He Y., et al. “Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus”. Journal of Clinical Microbiology8 (2005): 3718-3726.
  46. Buchholz UJ., et al. “Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity”. Proceedings of the National Academy of Sciences of the United States of America26 (2004): 9804-9809.
  47. Fu Y., et al. “Recent progress in microRNA-based delivery systems for the treatment of human disease”. ExRNA24 (2019): 1-14.
  48. Wei S., et al. “MicroRNA delivery through nanoparticles”. Journal of Controlled Release (2019): 1-74.
  49. Bai Z., et al. “Non-viral nanocarriers for intracellular delivery of microRNA therapeutics”. Journal of Materials Chemistry B (2019): 1-17.
  50. Baumann V and Winkler J. “miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents”. Future Medicinal Chemistry 17 (2014): 1967-1984.
  51. Cheng J and Deming TJ. “Synthesis of polypeptides by ROP of NCAs”. Pept Mater 310 (2011): 1-26.
  52. Koynova R., et al. “An intracellular lamellar-nonlamellar phase transition rationalizes the superior performance of some cationic lipid transfection agents”. Proceedings of the National Academy of Sciences of the United States of America39 (2006): 14373-14378.
Citation: Bati Leta and Urge Gerema. “MicroRNA: A Novel Approach for the Treatment and Vaccination of COVID-19”. EC Microbiology 18.5 (2022): 43-50.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


May Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the May issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before June 07, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.